RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
RETA
Delisted
RETA was delisted on the 25th of September, 2023.
214 hedge funds and large institutions have $3.27B invested in Reata Pharmaceuticals, Inc. Class A Common Stock in 2020 Q1 according to their latest regulatory filings, with 33 funds opening new positions, 78 increasing their positions, 71 reducing their positions, and 33 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
less funds holding
Funds holding: →
28% less capital invested
Capital invested by funds: $4.57B → $3.27B (-$1.29B)
41% less funds holding in top 10
Funds holding in top 10: 17 → 10 (-7)
Holders
214
Holding in Top 10
10
Calls
$129M
Puts
$56.6M
Top Buyers
| 1 | +$90.7M | |
| 2 | +$53M | |
| 3 | +$30.4M | |
| 4 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$16.4M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
+$15.3M |
Top Sellers
| 1 | -$61.5M | |
| 2 | -$47.5M | |
| 3 | -$24.5M | |
| 4 |
Renaissance Technologies
New York
|
-$19.8M |
| 5 |
BlackRock
New York
|
-$17.4M |